LOS ANGELES — Turn Therapeutics has appointed Robert Redfield, M.D., as Senior Advisor of Health Policy and Regulatory Affairs, adding a nationally recognized public health leader to guide the regulatory and clinical strategy for its lead investigational therapy, GX-03.
In the role, Dr. Redfield will provide strategic guidance on clinical development, public health considerations, and regulatory positioning as GX-03 advances through Phase 2 clinical trials. The company said his experience will support efforts to accelerate the therapy’s path toward patients.
“Dr. Redfield brings an incomparable level of experience, public health insight, and regulatory knowledge to the Turn ecosystem,” said Brad Burnam, chief executive officer of Turn Therapeutics. “As we advance GX-03 through mid-stage clinical development, his guidance will be instrumental in accelerating our regulatory path to patients.”
Dr. Redfield is a virologist and public health leader who previously served as the 18th director of the U.S. Centers for Disease Control and Prevention and as administrator of the Agency for Toxic Substances and Disease Registry. During his tenure, he oversaw responses to major public health challenges and led initiatives to strengthen scientific rigor, disease surveillance, and translational impact across federal health agencies.
He earned a Bachelor of Science from Georgetown University’s College of Arts and Sciences and received his medical degree from Georgetown University School of Medicine.
“Turn Therapeutics is pursuing a scientifically rigorous approach to addressing important unmet needs for large populations with few safe and effective options,” Dr. Redfield said. “I look forward to contributing my experience in clinical and regulatory policy to support the rapid advancement of GX-03.”
